Teng, Michele W.L.

Translational biology of osteosarcoma

Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 1,294

Combination cancer immunotherapies tailored to the tumour microenvironment

Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 944

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 894

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences

HER2/EGFR in Cancer ResearchCancer Immunotherapy and Biomarkers

Cited by 496

Cancer immunoediting by the innate immune system in the absence of adaptive immunity

O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., et al. (2012) · Journal of Experimental Medicine

Immune cells in cancerImmunotherapy and Immune Responses

Cited by 348

From mice to humans: developments in cancer immunoediting

Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J. (2015) · Journal of Clinical Investigation

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 337

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma

Guillerey, C., Harjunpää, H., Carrié, N., Kassem, S., Teo, T., Miles, K., Krumeich, S., Weulersse, M., Cuisinier, M., Stannard, K., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 300

Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy

Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. L., & Smyth, M. J. (2016) · Clinical Cancer Research

Immune Cell Function and InteractionCancer Immunotherapy and Biomarkers

Cited by 223

ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis

Nalkurthi, C., Schroder, W. A., Melino, M., Irvine, K. M., Nyuydzefe, M., Chen, W., Liu, J., Teng, M. W. L., Hill, G. R., Bertolino, P., et al. (2022) · JHEP Reports

Liver physiology and pathologyLiver Disease Diagnosis and Treatment

Cited by 75